Cancer Research Versailles No Abst  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, C.-L.
Right arrow Articles by Tam, P. K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.-L.
Right arrow Articles by Tam, P. K. H.
[Cancer Research 62, 6952-6958, December 1, 2002]
© 2002 American Association for Cancer Research


Immunology

Immunization with Epstein-Barr Virus (EBV) Peptide-pulsed Dendritic Cells Induces Functional CD8+ T-Cell Immunity and May Lead to Tumor Regression in Patients with EBV-positive Nasopharyngeal Carcinoma1

Chen-Lung Lin2, Wei-Feng Lo, Tzong-Hsien Lee, Yi Ren, Shiuh-Lin Hwang, Yu-Fan Cheng, Chao-Long Chen, Yu-Sen Chang, Steve P. Lee, Alan B. Rickinson and Paul Kwong Hang Tam

Department of Surgery, Chang Gung Memorial Hospital, Kaohsiung, 883 Taiwan [C-L. L., W-F. L., T-H. L., C-L. C.]; Department of Surgery, The University of Hong Kong Medical Centre, Queen Mary Hospital, Pokfulam Road, Hong Kong, SAR, China [C-L. L., Y. R., P. K. H. T.]; Department of Surgery, Kaohsiung Medical University, Kaohsiung, 807 Taiwan [S-L. H.]; Department of Radiology, Chang Gung Memorial Hospital, Kaohsiung, 883 Taiwan [Y-F. C.]; Graduate Institute of Basic Medical Sciences, Chang Gung University, Tao-Yuan, 333 Taiwan [Y-S. C.]; and CRC Institute for Cancer Studies, Medical School, University of Birmingham, Edgbaston, Birmingham, B15 2TT United Kingdom [S. P. L., A. B. R.]

Nasopharyngeal carcinoma (NPC), a common neoplasm in Southeast Asia, is EBV-positive and expresses a limited number of antigens, including latent membrane protein 2. In this study, autologous monocyte-derived dendritic cells were cultured from patients with advanced NPC, matured with cytokine, pulsed with HLA-A1101-, A2402-, or B40011-restricted epitope peptides from EBV latent membrane protein 2 and injected into inguinal lymph nodes. Sixteen patients with local recurrence or distant metastasis after conventional therapies received four injections at weekly intervals. Epitope-specific CD8+ T-cell responses were elicited or boosted in 9 patients receiving HLA-A1101- or A2402-restricted peptides, with stronger responses seen to the A1101 peptide. Furthermore, epitope-specific cytotoxicity was detectable in peripheral blood T cells harvested at 3-months after vaccination from A1101-responsive patients, and in 2 patients, this coincided with partial tumor reduction. Approaches leading to stronger and more sustained EBV-specific T-cell responses, therefore, may have therapeutic potential in the context of NPC.




This article has been cited by other articles:


Home page
BloodHome page
C. Gurer, T. Strowig, F. Brilot, M. Pack, C. Trumpfheller, F. Arrey, C. G. Park, R. M. Steinman, and C. Munz
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
Blood, August 15, 2008; 112(4): 1231 - 1239.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
S. L. Elliott, A. Suhrbier, J. J. Miles, G. Lawrence, S. J. Pye, T. T. Le, A. Rosenstengel, T. Nguyen, A. Allworth, S. R. Burrows, et al.
Phase I Trial of a CD8+ T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis
J. Virol., February 1, 2008; 82(3): 1448 - 1457.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
C. W. Tsang, X. Lin, N. H. Gudgeon, G. S. Taylor, H. Jia, E. P. Hui, A. T. C. Chan, C. K. Lin, and A. B. Rickinson
CD4+ T-Cell Responses to Epstein-Barr Virus Nuclear Antigen EBNA1 in Chinese Populations Are Highly Focused on Novel C-Terminal Domain-Derived Epitopes.
J. Virol., August 1, 2006; 80(16): 8263 - 8266.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
K. N. Heller, C. Gurer, and C. Munz
Virus-specific CD4+ T cells: ready for direct attack
J. Exp. Med., April 17, 2006; 203(4): 805 - 808.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P. Comoli, P. Pedrazzoli, R. Maccario, S. Basso, O. Carminati, M. Labirio, R. Schiavo, S. Secondino, C. Frasson, C. Perotti, et al.
Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes
J. Clin. Oncol., December 10, 2005; 23(35): 8942 - 8949.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. C. Straathof, A. M. Leen, E. L. Buza, G. Taylor, M. H. Huls, H. E. Heslop, C. M. Rooney, and C. M. Bollard
Characterization of Latent Membrane Protein 2 Specificity in CTL Lines from Patients with EBV-Positive Nasopharyngeal Carcinoma and Lymphoma
J. Immunol., September 15, 2005; 175(6): 4137 - 4147.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. C. M. Straathof, C. M. Bollard, U. Popat, M. H. Huls, T. Lopez, M. C. Morriss, M. V. Gresik, A. P. Gee, H. V. Russell, M. K. Brenner, et al.
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes
Blood, March 1, 2005; 105(5): 1898 - 1904.
[Abstract] [Full Text] [PDF]


Home page
Stem CellsHome page
A. Nencioni and P. Brossart
Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status
Stem Cells, July 1, 2004; 22(4): 501 - 513.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
C. Munz
Epstein-Barr Virus Nuclear Antigen 1: from Immunologically Invisible to a Promising T Cell Target
J. Exp. Med., May 17, 2004; 199(10): 1301 - 1304.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
G. S. Taylor, T. A. Haigh, N. H. Gudgeon, R. J. Phelps, S. P. Lee, N. M. Steven, and A. B. Rickinson
Dual Stimulation of Epstein-Barr Virus (EBV)-Specific CD4+- and CD8+-T-Cell Responses by a Chimeric Antigen Construct: Potential Therapeutic Vaccine for EBV-Positive Nasopharyngeal Carcinoma
J. Virol., January 15, 2004; 78(2): 768 - 778.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
P. Comoli, R. De Palma, S. Siena, A. Nocera, S. Basso, F. Del Galdo, R. Schiavo, O. Carminati, A. Tagliamacco, G. F. Abbate, et al.
Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma
Ann. Onc., January 1, 2004; 15(1): 113 - 117.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Brown, W. Gao, S. Alber, A. Trichel, M. Murphey-Corb, S. C. Watkins, A. Gambotto, and S. M. Barratt-Boyes
Adenovirus-Transduced Dendritic Cells Injected into Skin or Lymph Node Prime Potent Simian Immunodeficiency Virus-Specific T Cell Immunity in Monkeys
J. Immunol., December 15, 2003; 171(12): 6875 - 6882.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.